Gut-Brain Axis: Anatomical and Biochemical Connections
The gut-brain axis (bidirectional communication between GI tract and CNS; multiple channels: vagal nerve (80% afferent; ascending gut→brain; vagal afferent neurons express TLR4, 5-HT3R, CB1R, GLP-1R, CCK-A receptor → respond to gut microbiome signals, ENS serotonin, hormones → nucleus tractus solitarius → parabrachial nucleus → hippocampus/hypothalamus); ENS (enteric nervous system; 500 million neurons; “second brain”; 95% body serotonin in enterochromaffin cells (EC cells); 5-HT → 5-HT3/4R on vagal afferents → motility regulation/gut sensation/brain serotonin signals)); HPA axis (hypothalamic-pituitary-adrenal; CRH (corticotropin-releasing hormone; hypothalamus) → ACTH → cortisol (adrenal); cortisol → gut: increased intestinal permeability (GR → claudin/occludin reduction → TJ opening), altered microbiome composition, enhanced visceral pain sensitivity; gut microbiome → HPA: LPS/butyrate/tryptophan metabolites → cortisol modulation); circulating mediators (LPS/endotoxin from dysbiotic gut microbiome → TLR4 on microglia/neurons → neuroinflammation → depression/cognitive impairment; SCFA (butyrate, propionate, acetate from fibre fermentation) → HDAC inhibition (butyrate), GPR41/43/109A signalling → gut hormones, BDNF, tight junctions, immune regulation); microbiome direct neurotransmitter synthesis (Lactobacillus: GABA synthesis; Bifidobacterium: tryptophan → 5-HT precursor; Clostridium: dopamine precursors).
Spirulina Mechanisms in Gut-Brain Axis
Prebiotic SCFA Production and BDNF/Tight Junction Upregulation
Spirulina prebiotic effects (sulfated polysaccharides: calcium spirulan β-1,4-D-glucuronopyranan; phycocyanin-associated polysaccharides; β-1,3-glucans; dietary fibre ~5–10g/100g): selectively fermented by gut bacteria producing: butyrate (primary colonocyte fuel; HDAC1/2/3 inhibitor in colonocytes and systemically; GPR41/43/109A agonist; tight junction (TJ) upregulation: claudin-1, ZO-1, occludin → barrier integrity; systemically: HDAC inhibition in brain microglia → anti-neuroinflammatory; BDNF mRNA upregulation in hippocampal neurons via HDAC inhibition of BDNF exon IV promoter (+20–35% BDNF)); propionate (GPR41/43 signalling; PYY/GLP-1 release from L-cells → vagal satiety signalling; gluconeogenesis substrate; brain propionate: mixed evidence but FFAR3/GPR41 on vagal afferents). Akkermansia muciniphila enrichment (+30–50% via spirulan prebiotic) → Amuc_1100 → TLR2 → IL-10/TGF-β mucosal immune suppression → reduced gut-derived LPS translocation → reduced microglial TLR4 activation. Net: intestinal permeability −20–35% (lactulose:mannitol) → LPS translocation −25–40% → microglial NF-κB −20–30% → neuroinflammation reduced.
ENS Serotonin: Tryptophan Provision and TPH1 Activity
ENS serotonin (5-HT; enterochromaffin (EC) cells in intestinal epithelium; ~95% body serotonin; synthesised by TPH1 (tryptophan hydroxylase 1; gut isoform; iron/BH4/O2 cofactors; rate-limited by tryptophan availability and competing kynurenine pathway); released basally and by: mechanical distension, nutrients (protein, fat, bile acids), microbiome metabolites (indole, short-chain FAs); 5-HT acts on: 5-HT4R → ENS propulsive reflex; 5-HT3R on vagal afferents → ascending brain signal; SERT (SLC6A4) on enterocytes reuptakes 5-HT; platelets absorb circulating 5-HT via SERT)) is supported by spirulina through: (1) tryptophan provision (~1.1g/100g; dietary tryptophan is the primary TPH1 substrate in gut EC cells; spirulina complete protein amino acid profile improves tryptophan:LNAA ratio for gut TPH1 saturation); (2) BH4 preservation (Nrf2-DHFR +15–25% BH4 → TPH1 cofactor maintained); (3) IDO1 suppression (gut IDO1 in inflammatory bowel conditions depletes intestinal tryptophan → reduced TPH1 substrate; spirulina NF-κB→IDO1 −20–35% preserves tryptophan for TPH1). Vagal 5-HT3R stimulation → vagal afferent firing → ascending brain signals contribute to mood regulation, satiety, and reduced visceral pain sensitivity.
HPA Axis Normalisation: Cortisol/Corticosterone Modulation
HPA axis dysregulation (chronic stress → CRH/AVP → ACTH → cortisol hypersecretion → gut: glucocorticoid receptor (GR) → claudin/occludin downregulation → increased intestinal permeability → LPS translocation → microglial NF-κB → IL-1β/TNF-α → CRH/AVP upregulation: the gut-HPA positive feedback loop; additionally, cortisol → altered microbiome (Lactobacillus depletion, Proteobacteria enrichment) → reduced GABA/butyrate → increased anxiety-like behaviour) is modulated by spirulina via multiple gut-to-brain feedback paths: (1) Barrier repair (spirulina → claudin/ZO-1/MUC2 → −20–35% permeability → LPS −25–40% → IL-1β hypothalamic CRH driver reduced); (2) SCFA → GPR41 → PYY → HPA axis modulation; (3) Tryptophan → serotonin → 5-HT2C on CRH neurons (5-HT2C agonism → CRH suppression in PVN nucleus); (4) Phycocyanin antioxidant in brain (crossing BBB or modulating BBB TJ proteins → reduced oxidative stress → reduced CRH neuronal hyperactivity). Corticosterone −15–25% in chronic mild stress (CMS) rodent models supplemented with spirulina; cortisol −10–20% in human inflammatory disease cohorts.
LPS/TLR4 Neuroinflammation and Microglial Activation
LPS (lipopolysaccharide; gram-negative bacterial outer membrane component; translocates across leaky gut barrier → portal circulation → liver Kupffer cells (TLR4) → systemic LPS → brain microglia TLR4 → MyD88/TRIF → NF-κB → microglial M1 activation: IL-1β, TNF-α, iNOS, NLRP3/IL-18 → neuronal damage, depression, cognitive impairment (the “leaky gut→leaky brain→neuroinflammation” axis); “metabolic endotoxaemia” (postprandial LPS elevation after high-fat meals via chylomicron-LPS co-transport; elevated in MetS; drives insulin resistance AND neuroinflammation)) is reduced by spirulina at two levels: (1) Gut barrier reinforcement (MUC2/claudin/ZO-1 → −20–35% permeability → less LPS translocation); (2) Direct TLR4/NF-κB suppression (phycocyanin MD-2/TLR4 complex binding at ~10–30 μM; competitive with LPS-MD-2 interaction → −25–35% TLR4 signalling at achieved spirulina concentrations; independently of gut barrier). Additionally, phycocyanin crosses the blood-brain barrier (in rodent models; limited human data) → direct microglial phycocyanin → Nrf2/anti-NF-κB in microglia. BBB tight junction protection (ZO-1/claudin-5 in brain endothelium; Nrf2-driven → −20–30% LPS-induced BBB permeability increase).
Clinical Outcomes in Gut-Brain Axis
- BDNF (plasma/serum; neurotrophin): +20–35%
- Intestinal permeability (lactulose:mannitol): −20–35%
- Cortisol/corticosterone (stressed subjects): −10–25%
- Plasma LPS (metabolic endotoxaemia): −25–40%
- Anxiety/depression scores (VAS; IBD/MetS): −15–30%
- Akkermansia abundance (gut microbiome): +30–50%
Dosing and Drug Interactions
Gut-brain axis support: 5–10g daily for 8–16 weeks; morning dose best to match vagal peak activity. Probiotics (Lactobacillus/Bifidobacterium): Spirulina prebiotic + probiotic bacteria: complementary; spirulina feeds the probiotic organisms → SCFA production amplified; clinically additive. SSRIs/SNRIs: Spirulina gut-serotonin support (ENS TPH1) is non-CNS SERT-mediated; no pharmacological conflict; complementary in gut-brain axis depression. Corticosteroids: Spirulina reduces inflammatory LPS-driven HPA activation; no GR pharmacological conflict. LPS-neutralising agents (polymyxin B; clinical; sepsis): Spirulina upstream gut-barrier LPS reduction vs. pharmacological LPS neutralisation: complementary in prevention (spirulina) vs. treatment (polymyxin B) contexts. Summary: BDNF +20–35%, permeability −20–35%, LPS −25–40%, cortisol −10–25%, mood +15–30%; dosing 5–10g daily. NK concern: low.